TriSalus Life Sciences Files 8-K on Operations and Shareholder Votes

TL;DR

TriSalus Life Sciences (TLSI) filed an 8-K detailing operational results and shareholder votes as of Aug 13.

AI Summary

TriSalus Life Sciences, Inc. filed an 8-K on August 15, 2024, reporting on matters including results of operations, financial condition, and submission of matters to a vote of security holders as of August 13, 2024. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on TriSalus Life Sciences' operational and financial status, as well as important information regarding votes by its security holders.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial updates, not indicating immediate significant risk.

Key Players & Entities

• TriSalus Life Sciences, Inc. (company) — Registrant
• August 13, 2024 (date) — Earliest event reported
• August 15, 2024 (date) — Date of report
• MedTech Acquisition Corp (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
• $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke

Filing Documents

• tm2421775d1_8k.htm (8-K) — 37KB
• tm2421775d1_ex99-1.htm (EX-99.1) — 89KB
• 0001104659-24-089936.txt ( ) — 357KB
• tlsi-20240813.xsd (EX-101.SCH) — 3KB
• tlsi-20240813_def.xml (EX-101.DEF) — 26KB
• tlsi-20240813_lab.xml (EX-101.LAB) — 36KB
• tlsi-20240813_pre.xml (EX-101.PRE) — 25KB
• tm2421775d1_8k_htm.xml (XML) — 5KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 15, 2024, TriSalus Life Sciences, Inc. (the "Company") issued a press release providing a business update and announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On August 13, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of June 26, 2024, the record date for the Annual Meeting, the aggregate voting power of the outstanding shares of the Company entitled to vote at the Annual Meeting was 31,455,515. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number. Proposal 1: Election of Directors The Company's stockholders elected the four persons listed below as Class I directors, each to serve until the Company's 2027 Annual Meeting of Stockholders, and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Anil Singhal 15,581,603 53,394 2,206,892 Kerry Hicks 15,552,616 82,381 2,206,892 Liselotte Hyveled 15,586,944 48,053 2,206,892 Sean Murphy 15,611,916 23,081 2,206,892 Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,841,461 427 1 -

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated August 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2024 TriSalus Life Sciences, Inc. By: /s/ Sean Murphy Name: Sean Murphy Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR